Synapsin is a prescription therapy used for cognitive support.

Patients seeking support for cognitive support may qualify after evaluation by a licensed provider.

Yes. Synapsin is a compounded nasal spray that requires a valid prescription from a licensed provider. A telehealth consultation and medical intake are required before dispensing to ensure Synapsin is appropriate for your health history, goals, and current medications.

Synapsin is generally well-tolerated at therapeutic doses. Mild nasal irritation, congestion, or transient burning upon administration are the most commonly reported effects. Some patients report mild headache or lightheadedness following initial doses, which typically resolves as the body adjusts. Transient changes in sleep quality have been noted, consistent with NAD+ influence on circadian and mitochondrial function. As with any compounded therapy, individual responses vary. Report any unusual or persistent symptoms to your provider.

Synapsin is not appropriate for patients who are pregnant or breastfeeding, as safety data in these populations is insufficient. Patients with a history of hormone-sensitive cancers should consult their provider before use given RG3's interaction with estrogen receptor pathways. Those with active nasal infections, significant nasal polyps, or recent nasal surgery should not use intranasal therapy until cleared by their provider. Synapsin has not been studied in pediatric populations and is not indicated for patients under 18. Disclose your full medical history and current medications before starting treatment.

RG3 has mild acetylcholinesterase inhibitory activity. Patients on cholinergic medications including donepezil or rivastigmine should disclose concomitant use, as effects may be additive. NAD+ influences sirtuin and PARP pathways — patients on PARP inhibitors or chemotherapeutic agents should discuss use with their oncologist before starting. Those on blood thinners or antiplatelet therapy should exercise caution, as ginseng-derived compounds may have mild anticoagulant properties. Always provide a complete medication list to your provider before beginning treatment.

Patients with a history of hormone-sensitive cancers, including breast or ovarian cancer, should not use Synapsin without thorough provider evaluation given RG3's interaction with estrogen receptor signaling. Those with neurodegenerative conditions including Alzheimer's or Parkinson's disease may be candidates for Synapsin but require close provider supervision and individualized dosing. Patients with chronic nasal conditions, autoimmune disorders, or significant hepatic impairment require careful provider review before starting. Your provider requires a complete medical history before prescribing and will determine whether Synapsin is appropriate given your individual health profile.